Deletion of TP53 gene, under routine assessment by fluorescence in situ hybridization analysis, connects with the worst prognosis in chronic lymphocytic leukemia (CLL). The presence of isolated TP53 mutation (without deletion) is associated with reduced survival in CLL patients. It is unclear how these abnormalities are selected and what their mutual proportion is. We used methodologies with similar sensitivity for the detection of deletions (interphase fluorescence in situ hybridization) and mutations (yeast functional analysis) and analyzed a large consecutive series of 400 CLL patients; a subset of p53-wild-type cases (n = 132) was screened repeatedly during disease course. The most common type of TP53 inactivation, ie, mutation accompanied by deletion of the remaining allele, occurred in 42 patients (10.5%). Among additional defects, the frequency of the isolated TP53 mutation (n = 20; 5%) and the combination of 2 or more mutations on separate alleles (n = 5; 1.3%) greatly exceeded the sole deletion (n = 3; 0.8%). Twelve patients manifested defects during repeated investigation; in all circumstances the defects involved mutation and occurred after therapy. Monoallelic defects had a negative impact on survival and impaired in vitro response to fludarabine. Mutation analysis of the TP53 should be performed before each treatment initiation because novel defects may be selected by previous therapies.

Department of Internal Medicine Hematooncology University Hospital Brno and Faculty of Medicine Masaryk University 62500 Brno Czech Republic

References provided by Crossref.org

ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-2024 update

Patient-derived xenograft models of ALK+ ALCL reveal preclinical promise for therapy with brigatinib

Evolution of TP53 abnormalities during CLL disease course is associated with telomere length changes

Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options

TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics

ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation

Expression of COBLL1 encoding novel ROR1 binding partner is robust predictor of survival in chronic lymphocytic leukemia

Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells

Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?

TP53 mutation analysis in chronic lymphocytic leukemia: comparison of different detection methods

Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia

Identification of novel sequence variations in microRNAs in chronic lymphocytic leukemia